Vasculature News and Research

RSS

Business update from Cardima

Cardima, Inc., a medical device company focused on the diagnosis and treatment of atrial fibrillation (“AF”), is providing the following update on its progress, recent activities and upcoming milestones.

12 Oct 2009

Medtronic launches Captivia Delivery System for Valiant Thoracic Stent Graft

Adding to its market-leading portfolio of innovative medical technology for endovascular aortic repair (EVAR), Medtronic, Inc., announced today the CE (Conformité Européene) mark and international launch of the Captivia Delivery System for the Valiant Thoracic Stent Graft, a minimally invasive treatment for aneurysms and other lesions of the thoracic aorta.

9 Oct 2009

940nm wavelength laser is superior for treating facial spider veins: BUSM researchers

Researchers from Boston University School of Medicine (BUSM) have concluded that the 940nm wavelength laser is superior for treating facial spider veins (telangiectasias) as compared to the 532nm wavelength laser. The findings, which appear in the recent issue of Lasers in Surgery and Medicine, are the first time these lasers were tested against each other for superiority.

7 Oct 2009

Researchers visualize vasculature within native liver cyst walls of human ADPKD patients

As part of an effort to develop effective medical therapies that block the progression of liver cyst growth in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD), researchers at the University of Colorado Anschutz Medical Center have found that the liver cyst walls develop and maintain a vasculature as they grow out from the body of the liver and that factors released by epithelial cells that line the liver cyst wall lumen can drive the proliferation and development of vascular endothelial cells.

24 Sep 2009

Invatec launches a 3-dimensional distal Embolic Protection System for Carotid Artery Stenting

Invatec, a comprehensive innovator of interventional products, today introduced FiberNet®, a 3-dimensional distal Embolic Protection System (EPS) for Carotid Artery Stenting with the lowest crossing profile (0.031’’) and highest performance capabilities on the market, manufactured by Lumen Biomedical. FiberNet provides superior deliverability and can be used in vessels ranging from 3.5 to 7 mm.

21 Sep 2009

Pervasis Therapeutics raises funds to support clinical development programs

Pervasis Therapeutics, Inc. today announced that it completed the initial closing of a $17 million third round of financing. The proceeds will be used primarily to support the company's ongoing clinical development programs, including PVS-10200, a biologically active therapy designed to reestablish healthy vasculature following common interventions to treat peripheral arterial disease (PAD) and potentially other conditions.

17 Sep 2009

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

Bayer HealthCare today announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar(R) (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin(TM) - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany.

17 Sep 2009

Comprehensive CT scan gives better indication of significant coronary artery disease

A team of researchers led by Massachusetts General Hospital (MGH) radiologists has developed a computed-tomography-based protocol that identifies both narrowing of coronary arteries and areas of myocardial ischemia - restricted blood flow to heart muscle tissue - giving a better indication of clinically significant coronary artery disease.

16 Sep 2009

New biological process stimulates the growth of blood vessels

Researchers at the University of North Carolina at Chapel Hill School of Medicine and the College of Arts & Sciences have identified a new biological process that spurs the growth of new blood vessels.

15 Sep 2009

Fractal patterns and microchannels to advance tissue engineering

Utilizing fractal patterns similar to those created by lightning strikes, Victor Ugaz, associate professor in the Artie McFerrin Department of Chemical Engineering at Texas A&M University, has created a network of microchannels that could advance the field of tissue engineering by serving as a three-dimensional vasculature for the support of larger tissue constructs, such as human organs.

18 Aug 2009

A new prostate cancer "homing device" for drug delivery

A new prostate cancer "homing device" could improve detection and allow for the first targeted treatment of the disease. A team of Purdue University researchers has synthesized a molecule that finds and penetrates prostate cancer cells and has created imaging agents and therapeutic drugs that can link to the molecule and be carried with it as cargo.

6 Jul 2009

Scientists shed new light on why pancreatic cancer drugs can fail

Cancer Research UK scientists led an international team of investigators who have discovered a new mechanism that may explain why pancreatic cancer patients are often resistant to a common chemotherapy treatment called gemcitabine, according to a study published in Science.

22 May 2009

New evidence of how high glucose damages blood vessels could lead to new diabetes treatments

New evidence of how the elevated glucose levels that occur in diabetes damage blood vessels may lead to novel strategies for blocking the destruction, Medical College of Georgia researchers say.

12 May 2009

Peregrine's PS-targeting antibodies highlighted in AACR Annual Meeting studies

Peregrine Pharmaceuticals, Inc. has reported that two preclinical studies presented during the AACR 100th Annual Meeting 2009 provided further confirmation of the immunomodulatory mechanisms contributing to the anti-tumor activity of its phosphatidylserine (PS) targeting antibodies.

22 Apr 2009

New drug to target tumor cells and blood vessels

Researchers at the University of Southern California have identified a new drug compound that appears to target tumor cells and surrounding blood vessels without the negative side effects typically associated with Cox-2 inhibitors.

21 Apr 2009

New drug to target tumor cells and blood vessels

21 Apr 2009

Brain metastases hijack neuron-supporting cells to resist chemotherapy

Cancer that spreads to other organs finds a particularly inviting hideout in the brain, where these metastases are usually far harder to treat than they are in other locations.

20 Apr 2009

Cordex Pharma files ATPace formulation patent

Cordex Pharma, Inc. has announced today that it has filed a formulation patent covering its lead product, ATPace.

4 Mar 2009

Angiogenesis inhibitors, study points to limitations, solutions

A new generation of cancer drugs designed to starve tumors of their blood supply - called "angiogenesis inhibitors"-succeeds at first, but then promotes more invasive cancer growth-sometimes with a higher incidence of metastases, according to a new study in animals.

2 Mar 2009

Targeted nanospheres find, penetrate, then fuel burning of melanoma

Hollow gold nanospheres equipped with a targeting peptide find melanoma cells, penetrate them deeply, and then cook the tumor when bathed with near-infrared light. When heated with lasers, the actively targeted hollow gold nanospheres did eight times more damage to melanoma tumors in mice than did the same nanospheres that gathered less directly in the tumors.

23 Feb 2009